1. Home
  2. SVRA vs MTLS Comparison

SVRA vs MTLS Comparison

Compare SVRA & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SVRA
  • MTLS
  • Stock Information
  • Founded
  • SVRA 2007
  • MTLS 1990
  • Country
  • SVRA United States
  • MTLS Belgium
  • Employees
  • SVRA N/A
  • MTLS N/A
  • Industry
  • SVRA Biotechnology: Pharmaceutical Preparations
  • MTLS Computer Software: Prepackaged Software
  • Sector
  • SVRA Health Care
  • MTLS Technology
  • Exchange
  • SVRA Nasdaq
  • MTLS Nasdaq
  • Market Cap
  • SVRA 433.8M
  • MTLS 349.7M
  • IPO Year
  • SVRA N/A
  • MTLS 2014
  • Fundamental
  • Price
  • SVRA $2.58
  • MTLS $5.33
  • Analyst Decision
  • SVRA Buy
  • MTLS
  • Analyst Count
  • SVRA 5
  • MTLS 0
  • Target Price
  • SVRA $5.60
  • MTLS N/A
  • AVG Volume (30 Days)
  • SVRA 1.3M
  • MTLS 100.3K
  • Earning Date
  • SVRA 08-11-2025
  • MTLS 07-24-2025
  • Dividend Yield
  • SVRA N/A
  • MTLS N/A
  • EPS Growth
  • SVRA N/A
  • MTLS N/A
  • EPS
  • SVRA N/A
  • MTLS 0.11
  • Revenue
  • SVRA N/A
  • MTLS $311,850,851.00
  • Revenue This Year
  • SVRA N/A
  • MTLS $6.42
  • Revenue Next Year
  • SVRA N/A
  • MTLS $8.33
  • P/E Ratio
  • SVRA N/A
  • MTLS $50.34
  • Revenue Growth
  • SVRA N/A
  • MTLS 2.98
  • 52 Week Low
  • SVRA $1.89
  • MTLS $3.93
  • 52 Week High
  • SVRA $4.74
  • MTLS $9.69
  • Technical
  • Relative Strength Index (RSI)
  • SVRA 59.80
  • MTLS 40.58
  • Support Level
  • SVRA $2.25
  • MTLS $5.25
  • Resistance Level
  • SVRA $2.39
  • MTLS $6.19
  • Average True Range (ATR)
  • SVRA 0.15
  • MTLS 0.22
  • MACD
  • SVRA 0.04
  • MTLS -0.05
  • Stochastic Oscillator
  • SVRA 88.61
  • MTLS 7.98

About SVRA Savara Inc.

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

About MTLS Materialise NV

Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.

Share on Social Networks: